Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
w8s0y5QjHbtCHdNK
